Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
w8s0y5QjHbtCHdNK
